Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Avalo Therapeutics (AVTX) Return on Capital Employed (2016 - 2025)

Avalo Therapeutics' Return on Capital Employed history spans 11 years, with the latest figure at 0.68% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 9.0% year-over-year to 0.68%; the TTM value through Dec 2025 reached 0.68%, down 9.0%, while the annual FY2025 figure was 0.6%, 26.0% up from the prior year.
  • Return on Capital Employed reached 0.68% in Q4 2025 per AVTX's latest filing, down from 0.56% in the prior quarter.
  • In the past five years, Return on Capital Employed ranged from a high of 0.36% in Q1 2024 to a low of 2.92% in Q4 2022.
  • Average Return on Capital Employed over 5 years is 1.52%, with a median of 1.37% recorded in 2022.
  • Peak YoY movement for Return on Capital Employed: crashed -171bps in 2022, then skyrocketed 255bps in 2024.
  • A 5-year view of Return on Capital Employed shows it stood at 1.21% in 2021, then tumbled by -141bps to 2.92% in 2022, then surged by 54bps to 1.33% in 2023, then soared by 56bps to 0.58% in 2024, then decreased by -16bps to 0.68% in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Return on Capital Employed are 0.68% (Q4 2025), 0.56% (Q3 2025), and 0.49% (Q2 2025).